NatWest Group Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by NatWest Group Plc, dated February 9, 2026, reports a transaction in the Company's own shares. The announcement details a share repurchase executed on February 9, 2026, as part of an existing buyback programme authorized on July 25, 2025.
Key Financial Metrics
The filing focuses on capital management activities rather than operational financial performance. Key metrics related to the transaction include:
- Shares Purchased: 841,455 Ordinary Shares
- Price Range: Highest price paid was 655.40 GBp; lowest price paid was 593.80 GBp.
- Average Price: Volume weighted average price paid was 620.30 GBp.
- Trading Venue: London Stock Exchange (LSE).
- Treasury Holdings: Following settlement, the Company holds 218,374,752 Ordinary Shares in treasury.
- Shares in Issue: 7,985,067,662 Ordinary Shares (excluding treasury shares).
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the reduction of shares in issue and the increase in treasury shares resulting from the buyback. The filing does not provide comparative data against a prior period for financial performance.
Guidance, Outlook, and Risks
The Company intends to cancel the repurchased Ordinary Shares. The transaction was executed pursuant to instructions issued to Merrill Lynch International (BofA). No specific guidance, outlook, or new risk factors were disclosed in this announcement. Detailed trade breakdowns are available via the attached Market Abuse Regulation disclosure.
Investor Verification Checklist
- Verify the total value of the buyback programme and the remaining authorization limit.
- Confirm the impact of the share cancellation on earnings per share (EPS) and total equity.
- Review the full trade breakdown attached to the filing for intraday execution details.
- Check subsequent filings for updates on the total number of shares repurchased under the July 2025 mandate.